Most people know NAD+ as an energy molecule — a coenzyme that helps cells produce ATP and power the body's daily functions. But the brain's relationship with NAD+ is far more complex, and far more consequential. As NAD+ levels decline with age, the effects on cognitive function, neuroinflammation, and long-term brain health are increasingly well-documented in the scientific literature.
Why the Brain Is Especially Vulnerable to NAD+ Decline
The brain is one of the most metabolically demanding organs in the body. Neurons require enormous amounts of energy to maintain their electrical activity, synthesize neurotransmitters, and repair DNA damage — all processes that depend on adequate NAD+ levels. A landmark 2019 review published in Cell Metabolism described NAD+ as a "pivotal metabolite" involved in cellular bioenergetics, genomic stability, mitochondrial homeostasis, and adaptive stress responses, noting its central role in counteracting neurodegenerative diseases including Alzheimer's and Parkinson's.[1]
The problem is that NAD+ levels in the brain decline steadily with age. This decline is driven by several converging factors: increased activity of NAD+-consuming enzymes (particularly CD38 and PARP-1), reduced biosynthesis from dietary precursors, and the accumulating burden of oxidative stress and inflammation that characterizes aging tissue. As NAD+ falls, the mitochondria in neurons become less efficient, reactive oxygen species accumulate, and the brain's capacity for self-repair diminishes.
NAD+ and Neuroinflammation
One of the most significant downstream effects of NAD+ depletion in the brain is neuroinflammation — the chronic, low-grade activation of the brain's immune cells (microglia) that is now recognized as a key driver of cognitive decline. A 2021 study published in the Journal of Neuroinflammation demonstrated that NAD+ administration in a chronic cerebral hypoperfusion model rescued cognitive deficits and inhibited neuroinflammation by protecting mitochondria and reducing reactive oxygen species production. The mechanism involved activation of the Sirt1/PGC-1α pathway — a critical regulator of mitochondrial function and oxidative stress response.[2]
This finding is significant because it suggests NAD+ does not merely provide energy to neurons — it actively modulates the inflammatory environment in which they operate. When NAD+ is sufficient, sirtuins (a family of proteins that depend on NAD+ as a cofactor) can suppress inflammatory gene expression and promote cellular resilience. When NAD+ is depleted, this protective brake is released.
The Role of NMN and NR as NAD+ Precursors
Because NAD+ itself is not easily absorbed when taken orally, researchers have focused on precursor molecules — compounds that the body can convert into NAD+ through established metabolic pathways. The two most clinically studied are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).
A 2024 study published in Cell Death & Disease found that NMN supplementation restored NAD+ levels in Alzheimer's disease models and activated the ATF4-dependent mitochondrial unfolded protein response — a quality-control pathway that clears damaged proteins from neurons. NMN treatment reduced amyloid-β and tau pathology, decreased neuronal loss, and ameliorated brain atrophy, leading to improved memory performance and delayed disease progression in the study model.[3]
In a 2024 randomized placebo-controlled pilot trial published in GeroScience, NR supplementation at 1 gram per day for 10 weeks safely increased blood NAD+ levels by 2.6-fold in older adults with mild cognitive impairment. While the study was too small and brief to detect significant cognitive changes, it confirmed the safety and biological activity of NR in a vulnerable population — an important first step toward larger efficacy trials.[4]
Intravenous NAD+ and the Brain
Intravenous NAD+ delivery offers a distinct advantage over oral precursors: it bypasses the digestive system entirely and delivers NAD+ directly into the bloodstream, where it can be taken up by tissues — including the brain — without the conversion steps required by NMN or NR. A 2019 pilot study published in Frontiers in Aging Neuroscience characterized the pharmacokinetics of IV NAD+ infusion in humans, finding that NAD+ is "rapidly and completely removed from the plasma" during infusion, indicating active metabolic uptake throughout the body.[5]
Many patients who receive IV NAD+ infusions report improvements in mental clarity, focus, and mood — effects that are consistent with the known role of NAD+ in supporting mitochondrial function and neurotransmitter synthesis. While large-scale randomized trials specifically examining IV NAD+ and cognition are still underway, the mechanistic evidence is compelling and the clinical experience at wellness clinics is consistently positive.
What This Means for Longevity-Focused Individuals
The research on NAD+ and brain health points toward a clear principle: maintaining adequate NAD+ levels throughout life is not just about energy — it is about preserving the brain's capacity to repair itself, regulate inflammation, and sustain the metabolic activity that underlies memory, focus, and mood. A 2025 opinion piece in Trends in Endocrinology & Metabolism described NAD+ augmentation as "a promising multi-target therapeutic approach for neurodegenerative diseases," citing strong preclinical evidence and encouraging early-phase clinical trial results.[6]
At Nectar Wellness, our NAD+ IV infusions are administered by licensed registered nurses in a calm, private setting. Sessions typically run 2–4 hours, allowing for a slow, controlled infusion rate that maximizes comfort and absorption. For those interested in a longevity-focused approach to brain health, NAD+ therapy represents one of the most mechanistically grounded options currently available.
"NAD+ plays a pivotal role in cellular bioenergetics, genomic stability, mitochondrial homeostasis, and adaptive stress responses — and its decline with age is directly linked to neurodegenerative disease." — Lautrup et al., Cell Metabolism, 2019